This website uses cookies in order to improve our services. If you proceed visiting this website you accept the usage of cookies. For more info please read our Data Privacy statement.

 

Multiple Cancer Testing NGS Gene Panels


General Cancer Testing | Brain & CNS Cancer | Breast & Ovarian Cancer | Colorectal & Prostate Cancer | Endocrine & Thyroid Cancer | Gastric Cancer | Hematologic Cancer | Kidney Cancer | Lung Cancer | Pancreatic Cancer | Skin Cancer & Melanoma | Solid Tumors | Less Common Cancers


A number of genetic predispositions that can be related to various cancer types including mutations in regulatory genes are already described. In total a few hundred genes are described that are clinically relevant for different cancer types or that are believed to be associated with higher risk for developing cancer. 

On this page you will find a list of cancer panels from different commercial or service provider that target genes relevant for different cancer types. The panels differ in the number of genes that are sequenced and enable diagnosis (screening) for multiple cancer types. The number of targeted genes differs from only a few genes up to more than 400 genes depending on the panel. Therefore, the application of these panels might be limited to the investigation of few cancer types or of various cancer types.

Cancer panels with more specific applications for individual cancer types can be found in the corresponding category.


Universal Cancer Genetic Testing Panels

Ion AmpliSeq™ Transcriptome Human Gene Expression Kit

The Ion AmpliSeq™ Transcriptome Human Gene Expression Kit enables the simultaneous measurement of the expression levels of over 20,000 human RefSeq genes in a single assay. Providing the ability to work directly with low input levels of total RNA derived from challenging samples such as formalin-fixed paraffin-embedded (FFPE) tissue or other samples with degraded RNA, the Ion AmpliSeq™ Transcriptome Human Gene Expression Kit is ideal for those interested in obtaining comprehensive, highly sensitive, and easily obtained gene expression measurements from a wide range of RNA sources.
Source: Thermo Fisher

Website

TruSight One

The TruSight One sequencing panel provides clinical genomics research laboratories with an affordable solution for managing a diverse assay portfolio. Developed by Illumina, the TruSight One sequencing panel provides comprehensive coverage of > 4,800 clinically relevant genes. Laboratories can analyze all of the genes on the panel or choose to focus on a specific subset. Use of this panel enables expansion of existing menus, streamlining of workflows, or creation of an entire portfolio of sequencing options. The result is increased productivity, reduced handling errors, decreased laboratory costs, and consistent reporting.
Source: Illumina

Website


EGFR Gene Panels

EGFR MASTR

The EGFR MASTR assay amplifies exons 18 to 21 of the EGFR gene and consists of 4 amplicons in a single multiplex PCR reaction. Amplicon sizes range from 100 bp to 180 bp enabling mutation detection in FFPE derived DNA.
The Epidermal Growth Factor Receptor (EGFR) is a cellular transmembrane receptor found on the cell surface of tumour cells. It is activated by the binding of the EGF or other growth factors which finally stimulates cell proliferation. Mutations in the tyrosine kinase domain, comprised by exons 18-21, of the EGFR gene increase the activity of the intracellular signaling cascade resulting in uncontrolled proliferation of the tumor cells, such as non-small cell lung cancer (NSCLC). Identifying the TK domain mutations is applied in guiding targetted therapy strategies with tyrosine kinase inhibitors.
Source: multiplicom

Website


General Cancer Testing NGS Panels

Accel-Amplicon 56G Oncology Panel

The Accel-Amplicon 56G Oncology Panel offers comprehensive and hotspot coverage of 56 clinically-relevant oncology-related genes, using a 263-amplicon design to generate multiplex libraries compatible with Illumina sequencing platforms. This product is a complete kit that includes all elements necessary for generating ready-to-sequence libraries, including primer pairs and indexed sequencing adapters.
Source: Swift biosciences

Website

ACE Extended Cancer Panel

The ACE Extended Cancer Panel has been designed to support both discovery research and clinical trials. It provides more coverage of gene pathways and functions known to be involved in cancer biology than any other panel commercially available (TABLE 1). Up until now discovery researchers have had to make a choice between the breadth of sequencing used to find novel variants in cancer-related genes, and the depth of sequencing needed to identify variants present at low allelic fraction. The Personalis Extended Cancer Panel is the first service to combine the breadth of coverage for novel variant discovery across key cancer pathway genes, with the sequencing depth needed to detect variants present at low allelic fraction.
Source: Personalis

Website

ACE Extended Cancer Panel for RNA

Personalis’ ACE Extended Cancer Panel for RNA analysis allows for an unparalleled detection of unique variant types not identifiable by DNA sequencing analysis alone. Our panel is the first of its kind and targets the coding RNA of the over 1,300+ cancer panel genes, providing detection of important cancer associated features. For example, due to the breadth of our ACE Cancer Panel RNA sequencing, we are able to identify SNVs, Indels, gene expression levels, and gene fusion events in a very wide array of cancer-associated genes. Personalis’ ACE Extended Cancer Panel for RNA allows for extensive gene fusion discovery of both clinically actionable* fusions involving critical genes such as ALK, ROS1 and RET and novel fusions involving other targeted genes that might otherwise be missed.
Source: Personalis

Website

Cancer Hotspot Panel (NGS Panel)

covering most frequent mutations in genes ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL

Source: Centogene

CANCERNEXT

Ambry utilizes NGS to offer a comprehensive panel for hereditary breast, ovarian, uterine, and colorectal cancers. Genes on this panel include APC, ATM, BARD1, BRCA1, BRCA2, BRIP1, BMPR1A, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, GREM1, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, SMAD4, SMARCA4, STK11, and TP53. Full gene sequencing is performed for 30 of the genes (excluding EPCAM and GREM1). Gross deletion/duplication analysis is performed for all 32 genes.
Source: Ambry Genetics

CANCERNEXT-EXPANDED

Ambry utilizes NGS to offer a comprehensive hereditary pan-cancer panel. Genes on this panel include: APC, ATM, BAP1, BARD1, BRCA1, BRCA2, BRIP1, BMPR1A, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, FH, FLCN, GREM1, MAX, MEN1, MET, MITF, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, TMEM127, TP53, TSC1, TSC2, VHL. Full gene sequencing is performed for 47 of the genes (excluding EPCAM and GREM1). For MITF, only the status of the c.952G>A (p.E318K) alteration is analyzed and reported. Gross deletion/duplication analysis is performed for 48 genes (excluding MITF).
Source: Ambry Genetics

Cancer Panel (Tumor-standard-paired)

Targeted genes: ABL1, AKT1, AKT2, AKT3, ALK, APC, AR, RSAF, ATM, AURKA, AURKB, AXIN1, AXL, BaP1, BARD1, BCL2, BCL2L1, BCL2L2, BLM, BRAF, BRCA1, BRCA2, BRD2, BRD3, Brd4, BRT, BRIP1, BTK, CBFB, CCND1, CCND2, CCND3, CCNE1,
CD22, CD274, CD79a, CD79b, CDH1, CDK12, CDK4, CDKN1A, CDKN2A, CHEK1, CHEK2, CREBBP, CRKL, DDR2, DDX3X, EGFR, EPHA7, ERBB2, ErbB3, ErbB4, ESR1, EZH2, FAM175A, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FHIT, FLT1, FLT3, FLT4, FRS2, GATA2, GNA11, GNAQ, HDAC1, HDAC4, HDAC7, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR, KIT, KRAS, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAPK1, MCL1, MDM2, MET, MLH1, MPL, MRE11A, MS4A1, MSH2, MSH6, mTOR, MUTYH, MYC, MyD88, NBN, NF1, NF2, NFE2L2, NFKBIA, NOTCH1, NOTCH2, NOTCH3, NRAS, NT5C2, NTRK1, PALB2, PDGFRA, PDGFRB, PDK1, PIK3CA, PIK3CB, PIK3CG, PMS2, PTCH1, PTEN, RAC1, RAD51, RAF1, RANBP2, RARE, RB1, RET, rictor, ROS1, RRM1, RUNX1, SDHB, SMO, SOX2, SRC, STAT3, STAT5b, STK11, TERC, TERT, TGFBR2, TP53, TSC1, TSC2, VEGFA, WT1, XPO1

Source: Mendelics

Cancer Predisposition

Determination of cancer predisposition is vital for prevention and early detection of the disease. Early diagnosis of cancer will ensure the immediate start of treatment, which is a key to increasing the survival and recovery. Significant difference between the survival rates of early stage and advanced stage of cancer points out the need for risk assessment of the disease.
Identification of genetic susceptibility to hereditary cancer syndromes enables to implement risk-reduction strategies, estimate familial cancer risk and identify at-risk family members.
Cancer predisposition testing at Asper Biotech includes two next generation sequencing based panels, allowing to analyze multiple genes associated with an increased risk for a wide range of cancers.
Source: Aspen Biotech
Aspen Biotech offers two NGS panels one for 93 genes and one for 109 genes.

Website

CANCER PREDISPOSITION PANEL (Panel 170 PLUS)

Targets over 1700 exons, spanning 94 genes of interests and additional 284 SNPs occurring in 78 different genes - associated with a predisposition towards cancer.

Panel 170 PLUS includes genes associated with both common (e.g., breast cancer, prostate, hematologic malignancies, colorectal, lung, kidney) and rare cancers. In addition, the set includes 284 SNPs found to correlate with cancer through genome-wide association studies (GWAS). Content selection was based on expert interpretation of the scientific literature and other high-quality resources.

Source: DNA Research Center

CANCER PREDISPOSITION PANEL (Panel "For Her")

Targets the whole exons, spanning 48 genes of interests and additional 22 SNPs occurring in 22 different genes - associated with a predisposition towards the most common female cancers.

Panel "For Her" includes genes associated with the cancers, like: breast, colorectal, lung and ovarian cancer. In addition, the set includes 22 SNPs found to correlate with analyzed cancers through genome-wide association studies (GWAS).

Source: DNA Research Center

CANCER PREDISPOSITION PANEL (Panel "For Him")

Targets the whole exons, spanning 54 genes of interests and additional 45 SNPs occurring in 45 different genes - associated with a predisposition towards the most common male cancers.

Panel "For Him" includes genes associatedcancers, like: prostate cancer, colorectal cancer, lung cancer, testicular germ cell tumor. In addition, the set includes 45 SNPs found to correlate with analyzed cancers through genome-wide association studies (GWAS).

Source: DNA Research Center

ClearSeq Comprehensive Cancer

This panel targets 151 key disease-associated genes that have been implicated in studies of a wide range of cancers (eg. breast, lung, colorectal, AML) and is designed for deep coverage of target bases for confident variant detection.
Compatible with SureSelect Target Enrichment System.
Source: Agilent

Website

ClearSeq Cancer

The ClearSeq Cancer panel Identify somatic variants in 47 genes targeting known COSMIC hotspots found to be associated with a broad range of cancer types as well as published drug targets.
Compatible with HaloPlexHS and HaloPlex Target Enrichment System.

Source: Agilent

Website

ClearSeq Human DNA Kinome

This panel targets a comprehensive set of kinases and kinase related genes for enrichment, including over 500 kinases and 612 genes. This panel is compatible with post-capture (SureSelectXT) and pre-capture (SureSelectXT2) pooling – (XT2 - pool up to 16 samples per enrichment) available.
Compatible with SureSelect Target Enrichment System.
Source: Agilent

Website

ClearSeq Human RNA Kinome

This panel targets a comprehensive set of kinases and kinase related transcripts for enrichment, including over 500 kinases and 612 genes.
Compatible with SureSelect Target Enrichment System.
Source: Agilent

Website

Comprehensive Cancer Panel

The differential diagnosis includes various hereditary cancer syndromes. For example, if the family history consists of multiple cases of ovarian cancer, this may be associated with a breast/ovarian cancer syndrome such as BRCA1 or BRCA2 or Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM). Thus, the OncogeneDx Comprehensive Cancer panel offers increased clinical sensitivity compared to testing only for the BRCA genes. Furthermore, panel testing is more cost effective than stepwise genetic testing (for example, ordering BRCA testing followed by additional genetic testing).
Tested genes
APC, ATM, AXIN2, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, FANCC, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, SCG5/GREM1, SMAD4, STK11, TP53, VHL, XRCC2

Source: GeneDx

Focus::CLL™

Focus::CLL™ is a unique NGS panel with 7 actionable markers that have value for prognosis. Based on the Focus::CLL™ result, each patient will receive the most suitable treatment tailored to their unique cancer.
Source. Cancer genetics

Website

FoundationOne

FoundationOne is a fully informative genomic profile that helps physicians make treatment decisions for patients with cancer by identifying the molecular growth drivers of their cancers and helping oncologists match them with relevant targeted therapeutic options.
Source: FoundationOne

Website

GeneRead DNAseq Targeted Panels V2

GeneRead DNAseq Targeted Panels V2 are the simplest tools for analyzing the genetic variants of a focused panel of genes via next-generation sequencing. Each panel consists of multiplex PCR primer sets to amplify exonic regions of a thoroughly researched panel of biologically and clinically relevant and disease-focused genes. GeneRead DNAseq Targeted Panels V2 can also be customized to include genes or other genomic regions tailored to your specific NGS project needs.
Source: Qiagen

Website

Guardant360®

Prior to Guardant360®, there has been no practical way to comprehensively detect resistance and sensitivity mutations outside of a tumor biopsy. Further, biopsies lose their relevance over time due to heterogeneity and evolution of a patient’s cancer in response to treatment. Now with Guardant360, a simple blood draw tests 70 genes including SNVs, CNVs, indels, and rearrangements across more than 150,000 base pairs, aiding in treatment management.
Source: Guardanthealth

Website

Human Cancer Predisposition Panel

The Human Cancer Predisposition GeneRead DNAseq Targeted Panel is a multiplexed PCR-based assay for targeted enrichment of the coding (exonic) regions of the 143 genes commonly mutated in 88 inherited oncogenic diseases.
This panel includes all genes that are known to cause heritable diseases that result in cancer in at least 50% of affected individuals, as well as other genes commonly mutated in cancer. Many of these genes have key mutations annotated that predispose a person to cancer.
Source: Qiagen

High/Moderate Risk Panel

Tested genes APC, ATM, BMPR1A, BRCA1, BRCA2, CDH1, CDKN2A, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, PTEN, SMAD4, STK11, TP53, VHL
Disorders:
Attenuated Familial Adenomatous Polyposis (AFAP)
Breast Cancer
Colorectal Cancer
Endometrial Cancer
Familial Adenomatous Polyposis (FAP)
Lynch Syndrome
Ovarian Cancer
Pancreatic Cancer
Uterine Cancer

Source: GeneDx

Human Clinically Relevant Tumor Panel

The Human Clinically Relevant Tumor GeneRead DNAseq Targeted Panel is a collection of multiplexed PCR primer assays for targeted enrichment of the key regions of 24 genes identified by medical groups and peer-reviewed research to be functionally relevant in the treatment of solid tumors. Clinically relevant mutations in these genes have been identified by guidelines and published opinions from groups such as the National Comprehensive Cancer Network (NCCN), College of American Pathologists (CAP), and American Society of Clinical Oncology (ASCO). There are many genes that are somatically mutated during carcinogenesis. However, few of these mutations have confirmed prognostic or diagnostic importance.
Source: Qiagen

Human Comprehensive Cancer Panel

The Human Comprehensive Cancer GeneRead DNAseq Targeted Panel is a collection of multiplexed PCR primer assays for targeted enrichment of the coding (exonic) regions of the 160 genes that are most commonly mutated in cancers with a recognizable oncogenic consequence. Mutations in these oncogenes and tumor suppressor genes are often relevant for tumor classification, and warrant extensive investigation to enhance the understanding of carcinogenesis. Cancer research continually identifies novel mutated carcinogenesis-related genes, or novel mutations in known oncogenic genes, elucidating new mechanisms of cancer progression or treatment evasion.
Source: Qiagen

iGene Cancer Panel

Covered Diseases / Risk Areas: 9 hereditary cancer syndromes: breast cancer, ovarian cancer, colorectal cancer, gastric cancer, pancreatic cancer, endometrial cancer, renal cell carcinoma, melanoma, and prostate cancer.
Targeted genes: APC, BMPR1A, BRCA1, BRCA2, CDH1, CDKN2A, MEN1, MLH1, MSH2, MSH6, MUTYH, NTRK1, PTCH, PMS2, PTEN, RET, SMAD4, STK11, TP53, and VHL
Source: ApolloGen

Inherited Cancer Panel

Our next-generation sequencing test is designed to detect mutations in the coding region of 52 genes associated with cancer, or increasing the risk for cancer onset. Our microarray test is designed to identify single exon deletions and duplications in the same 52 cancer-associated genes. Combining deletion/duplication data analyzed by microarray with next generation sequencing data will allow KDL to improve diagnostic yield and deliver more comprehensive results. This set of genes includes genes associated with: breast/ovarian/endometrial cancers; GI cancers, such as Lynch syndrome; renal and pancreatic cancers; melanoma; endocrine tumors, including multiple endrocrine neoplasia; and syndromes associated with single gene defects, such as Birt-Hogg-Dube, Bloom, Gorlin, Li-Fraumeni and Von-Hippel-Lindau, among others.
Source: Knight Diangostics Laboratories

Invitae Multi-Cancer Panel

The Invitae Multi-Cancer Panel analyzes 79 genes that are associated with hereditary cancers across eight major organ systems.
The Invitae Multi-Cancer Panel is designed to maximize diagnostic yield for patients with a personal or family history of mixed cancers affecting these organ systems. The genes selected for this panel include the aggregate of primary genes from each of the individual cancer panels to provide clinically relevant information pertaining to cancers across all the organ systems.
Genetic testing of these genes may confirm a diagnosis and help guide treatment and management decisions. Identification of a disease-causing variant would also guide testing and diagnosis of at-risk relatives.
Source: Invitae

Ion AmpliSeq™ RNA Cancer Panel

The Ion AmpliSeq™ RNA Cancer Panel is a screening tool designed against 50 oncogenes/tumor suppressor genes found in the COSMIC database. This panel has been developed as an RNA complement to the DNA-focused Ion AmpliSeq™ Cancer Hotspot Panel v2. The panel is a single pool of primers representing 50 oncogenes and tumor suppressor genes with coverage of KRAS, BRAF, and EGFR genes.
Source: Thermo Fisher

Website

Ion AmpliSeq™ Comprehensive Cancer Panel

The Ion AmpliSeq™ Comprehensive Cancer Panel provides highly multiplexed target selection of genes implicated in cancer research. Encompassing over 50% of the Wellcome Trust Sanger Institute Cancer Gene Census, this is the most comprehensive cancer gene panel available. With all-exon coverage of 409 genes, the Ion AmpliSeq™ Comprehensive Cancer Panel delivers fast, FFPE-compatible, target selection for a broad survey of key genes for semiconductor sequencing.
Source: Thermo Fisher

Website

Multiplicom’s Tumor Hotspot MASTR Plus assay

Multiplicom’s Tumor Hotspot MASTR Plus assay is provided as a ready-to-use kit that offers robust performance with minimum hands-on time. All reagents necessary to enable multiplex amplification of 252 amplicons (121-254 bp) in 4 PCR reactions are included. The assay builds on Multiplicom’s expertise of multiplex assays, and is further optimized to detect mutations using DNA derived from FFPE tumor samples, but is also compatible with FFT samples or detection of mutations in germline DNA.
Source Multiplicom

Website

NovoCR™

This test, tested and validated on over 400 patient samples, is available for patient diagnosis in China, provides an advanced cancer susceptibility gene screening solution for people with high risk of cancer. By analyzing germ line mutations in leukocytes or oral mucosa cells, NovoCRTM helps doctors diagnose cancer at the molecular level. It also offers risk assessment for relatives of the cancer patient, which helps cancer prevention through pre-emptive medical care. The Professional Version covers 106 genes in 16 types of cancer. The test, which offers extensive exon coverage, uses international databases such as HGMD, BIC, LOVD InSiGHT, and ClinVar and a Chinese database developed in collaboration with national experts.

Source: Novogene

NovoPM™ Cancer Panels

The NovoPM test provides a solution for solid cancer assessment and aids in developing a personalized cancer therapy strategy. The test, run on the Illumina HiSeq platform, identifies relevant cancer-related genomic alterations in individual samples. There is also a non-invasive NovoPM test which analyzes circulating tumor DNA (ctDNA) alterations in plasma. Each has two versions, “Standard” and “Professional”. The Standard Version contains 40 genes. The Professional Version sequences the coding region of 483 cancer-related genes and introns from 19 genes. This covers most major cancers (Lung, Colon, Esophageal, Gastric, Breast, etc.), examining selected genes based on National Comprehensive Cancer Network (NCCN) guidelines. The various versions of the NovoPM test have been validated on a total of 1,000 patient samples. In a research setting these assays can be used to help scientists develop potential therapeutics.

Source: Novogene

OncoDEEP DX

OncoDEEP DX focuses on 65 genes which, of course, have been associated to cancer but also have been chosen by pharmaceutical companies as target to develop drugs active upon the disease. If a variant in one of these genes is discovered, it should provide a good target and treatment opportunity which should be more effective. The first version V1 of OncoDEEP DX is based on AmpliSeq Cancer Hotspot Panel while the version V2 questions extra genes (e.g. the minimal list of genes to be sequenced for diagnostic purposes recommended by Institut National du Cancer).
Source: Oncoshare

Website

OncoGeneDx Custom Panel

Tested genes: APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CHEK2, EPCAM, FANCC, FH, FLCN, MAX, MEN1, MET, MITF, MLH1, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, RET, SCG5/GREM1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, TMEM127, TP53, TSC1, TSC2, VHL, XRCC2

Disorders:
Attenuated Familial Adenomatous Polyposis (AFAP)
Breast Cancer
Colorectal Cancer
Endometrial Cancer
Familial Adenomatous Polyposis (FAP)
Lynch Syndrome
Ovarian Cancer
Pancreatic Cancer
Paraganglioma
Pheochromocytoma
Renal Cancer
Uterine Cancer

Source: GeneDx

OncoRisk Plus

OncoRisk Plus (NGS panel for 89 genes)
AIP, ALK, APC, ATM, BAP1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1B, CDC73, CDH1, CDK4, CDKN1C, CDKN2A, CEBPA, CEP57, CHEK2, CYLD, DDB2, DICER1, DIS3L2, EPCAM, ERCC2, ERCC3, ERCC4, ERCC5, EXT1, EXT2, EZH2, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FH, FLCN, GATA2, GPC3, KIT, MAX, MEN1, MET, MLH1, MSH2, MSH6, MUTYH, NBN, NF1, NF2, NSD1, PALB2, PHOX2B, PMS2, PRF1, PRKAR1A, PTCH1, PTEN, RAD51C, RAD51D, RB1, RECQL4, RET, RUNX1, SBDS, SDHAF2, SDHB, SDHC, SDHD, SLX4, SMAD4, SMARCB1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, WRN, WT1, XPA, XPC
Source: CGC Genetics

OncoTRACE

OncoTRACE analysis uses next generation sequencing at ultra high coverage and consists in three steps: OncoTRACE enables the analysis of the tumor of the patient using 411-genes. OncoDEEP Clinical panel enables identification of variants specific to the patient. OncoTRACE enables routine semi-quantitative analysis of personalized variants along with hotspot variants related to targeted therapies and treatment resistance.
Source: OncoDNA

Website

Ovation® Cancer Panel Target Enrichment Systems

Ovation® Cancer Panel Target Enrichment Systems The Ovation Cancer Panel 2.0 Target Enrichment System enables target enrichment studies with 509 cancer genes using NuGEN's proprietary Single Primer Enrichment Technology and is a complete solution for generation of enriched, multiplexed libraries from low-input amounts of genomic DNA.
Source: nugene

Website

Ovation® Cancer Panel FFPE Target Enrichment System

The Ovation Cancer Panel FFPE Target Enrichment System is a pre-defined cancer panel for FFPE DNA and targets 344 cancer-related genes published in Nature Biotechnology 29, pp. 1024-1027 (2011). The product product can be used to interrogate both SNPs and CNVs in the same sequencing run.
Source: nugene

Website

Pan Cancer Somatic Panel

The Pan Cancer Somatic Panel was designed for use across multiple cancers. The initial panel targets 52 genes.

Website

Quantidex™ Pan Cancer Kit*

The Quantidex™ Pan Cancer Kit* is a next-generation sequencing (NGS) based workflow that incorporates both a multiplexed, gene specific PCR panel as well as supporting workflow elements, including the analytical and reporting features within one comprehensive kit. The kit, interrogates 46 gene regions (amplicons) within 21 genes, deemed to be of high clinical significance and potentially actionable* content in various human cancers. The scope of variants reported by the panel include >1,600 known COSMIC variants, including single nucleotide variants (SNVs), insertions-deletions (indels), and structural rearrangements targeted by the panel. A comprehensive NGS workflow, the kit includes all necessary reagents for pre-analytical DNA QC/quantification, gene specific PCR, library purification and quantification for sequencing with the Illumina chemistry.
Source: Asuragen

Website

Somatic Tumor Panel

The CeGaT Somatic Tumor Panel comprises 649 genes with known mutations that can have an impact on tumor development. In addition to sequencing exonic regions of these 649 genes we analyze selected translocations in 28 genes. For the detection of somatic mutations a normal tissue sample (usually blood) is needed in addition to a sample of the tumor. The identification of somatic mutations provides a more detailed diagnosis of tumors and can support treatment decision.
Source: CeGaT

SYMGENE targeted gene panel

The new SYMGENE targeted gene panel is designed to give pathologists and oncologists a competitive edge by offering clients competitively priced next- generation sequencing that isolates the 68 most actionable genes, for faster, more accurate, and more relevant results.
Source: Symbiodx

Website

SOMATIC 1 MASTR v2

The SOMATIC 1 MASTR v2 is a molecular assay (research use only) for the identification of all mutations in the NRAS,KRAS and BRAF genes in individuals with various types of cancer. Multiplicom’s SOMATIC 1 MASTR v2 assay is provided as a ready-to-use kit that offers robust performance with minimum hands-on time. All reagents necessary to enable multiplex amplification of 30 amplicons (168-255 bp) in three PCR reactions are included, for complete coverage of all coding sequences.
Source: multiplicom

Website

Accel-Amplicon Comprehensive TP53 Panel

The Accel-Amplicon Comprehensive TP53 Panel offers comprehensive coverage of all coding regions of the TP53 gene, using a 21-amplicon design to generate multiplex libraries compatible with Illumina sequencing platforms. This product is a complete kit that includes all elements necessary for generating ready-to-sequence libraries, including primer pairs and indexed sequencing adapters.
Source: Swift biosciences

Website

ThunderBolts™ Cancer Panel

The ThunderBolts™ Cancer Panel is a comprehensive next-generation sequencing (NGS) panel for profiling important cancer mutations. The ThunderBolts Cancer Panel enables researchers to rapidly detect and cost-effectively analyze mutations on precious FFPE (Formalin-Fixed Paraffin-Embedded), tissue, and Liquid Biopsy samples (circulating tumor DNA or ctDNA). The ThunderBolts Cancer Panel uses single molecule PCR to target 50 known cancer genes including tumor suppressors, mutation hotspots and drug resistance markers. The panel also features industry breakthroughs in sequence coverage and uniformity, allelic sensitivity, sample flexibility, workflow, and cost.
Source: Raindance technologies

Website

TruSight Cancer

The TruSight Cancer includes genes associated with both common (e.g., breast, colorectal) and rare cancers. In addition, the set includes 284 SNPs found to correlate with cancer through genome-wide association studies (GWAS). Content selection was based on expert curation of the scientific literature and other high-quality resources.
Source: Illumina

Website

xGen® Pan-Cancer Panel

The xGen® Pan-Cancer Panel v1.5 consists of 7816 individually synthesized and quality controlled xGen Lockdown® Probes that allow enrichment of 127 significantly mutated genes implicated across 12 tumor tissue types to enable deeper coverage during sequencing.

Source: IDT


Hereditary Cancer NGS Panels

CANCER NEXTGEN SEQUENCING (NGS) PANEL

This NextGen test analyzes multiple genes involved in multiple hereditary cancer syndromes which are inherited in an autosomal dominant manner. Several types of cancers may be found in a pedigree and this test may help in the differential diagnosis and rule out particular syndromes by simultaneously analyzing multiple genes involved in hereditary cancers.The Cancer NextGen Sequencing Panel analyzes 35 genes that have been associated with hereditary cancers. For this NGS panel, the full coding regions, plus ~20bp of non-coding DNA flanking each exon, are sequenced for each of the genes.
Source: Prevention Genetics

Cancer Panel, Hereditary, Sequencing and Deletion/Duplication

Genes tested by Sequencing: ALK, APC, ATM, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN1B, CDKN2A, CHEK2 common mutations, FH, FLCN, MAX, MEN1, MET, MLH1, MSH2, MSH6, MUTYH, NBN, NF2, PALB2, PHOX2B, PMS2, PTEN, RAD51C, RAD51D, RB1, RET, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCB1,STK11, SUFU, TMEM127, TSC1, TSC2, TP53, VHL

Genes tested by Deletion/Duplication: ALK, APC, ATM, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN1B, CDKN2A, CHEK2 common mutations, EPCAM deletion only, FH, FLCN, MAX, MEN1, MET, MLH1, MSH2, MSH6, MUTYH, NBN, NF2, PALB2, PHOX2B, PMS2, PTEN, RAD51C, RAD51D, RB1, RET, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCB1,STK11, SUFU, TMEM127, TSC1, TSC2, TP53, VHL
Source: Arup Laboratories

Comprehensive hereditary cancer panel

Tested genes ALK, APC, ATM, BAP1, BLM, BMPR1A, BRIP1, CDC73, CDH1, CDK4, CDKN2A, CEBPA, CHEK2, CYLD, DDB2, DICER1, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, EXT1, EXT2, EZH2, FANCA, FANCC, FANCD2, FANCF, FANCG, FH, FLCN, GATA2, GDNF, HNF1A, HRAS, KIT, MEN1, MET, MITF, MLH1, MSH2, MSH6, MUTYH, NBN, NF1, NF2, NSD1, PALB2, PAX5, PDGFRA, PHOX2B, PMS1, PMS2, POT1, PRKAR1A, PTCH1, PTEN, RB1, RECQL4, RET, RUNX1, SBDS, SDHA, SDHB, SDHC, SDHD, SMAD4, SMARCB1, STK11, SUFU, TP53, TSC1, TSC2, VHL, WRN, WT1, XPA, XPC

Source: Centogene

ESTIMATE™

ESTIMATE™ Cancer Panel, a new multi-gene diagnostic test that provides increased sensitivity to the risk of malignancies by analyzing 32 genes associated with eight major malignant tumor types including: breast, colorectal, ovarian, endometrial, pancreatic, prostate, gastric cancers and melanoma.

ESTIMATE™ Cancer Panel will improve the quality of patient care by empowering healthcare providers with the knowledge of their patient’s risk for hereditary cancer as well as the appropriate medical management options available based on that risk. The test represents the next generation of hereditary cancer testing and will provide healthcare providers with clear and actionable information to improve patient care, regardless of whether the patient receives a positive or negative test result.

Source: Pentacorelab

Hereditary Cancer NGS Panel

Targeted Genes:(112) AIP, APC, ATM, ATR, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1B, CDH1, CDK4, CDKN1B, CDKN2A, CHEK2, CTNNB1, CYLD, DDB2, DICER1, EGFR, EGLN1, EPCAM, ERCC2, ERCC3, ERCC4, ERCC5, EXO1, EXT1, EXT2, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FH, FLCN, GALNT12, GPC3, HOXB13, HRAS, KIF1B, KIT, MAX, MC1R, MEN1, MET, MITF, MLH1, MPL, MRE11A, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, PALB2, PDGFRA, PICALM, PMS1, PMS2, POLD1, PRKAR1A, PRKDC, PRSS1, PTCH1, PTEN, PTPN11, RAD50, RAD51, RAD51C, RAD51D, RB1, RBBP8, RBM15, RECQL4, RET, ROBO2, SBDS, SDHA, SDHAF2, SDHB, SDHC, SDHD, SLX4, SMAD4, SMARCB1, STK11, SUFU, TERT, TMEM127, TP53, TSC1, TSC2, TSHR, TYR, VHL, WRN, WT1, XPA, XPC, XRCC2, XRCC3
Source: Fulgent Diagnostics

Hereditary Cancer panel

Targeted genes BRCA1, BRCA2, TP53, PTEN, ATM, BLM, PALB2, RAD51D, RAD51C, BRIP1, STK11, BARD1, PIK3CA, XRCC2, NBN, FANCC, SDHB, CHEK2, RECQL, CDH1, APC, MUTYH, MSH2, MSH6, MLH1, PMS2, EPCAM, RET, MEN1, NTRK1, RB1, MET, CDKN2A, CDK4, BaP1, AKT1, WT1, NF1, NF2

Source: Mendelics

Hereditary Cancer Syndromes, Comprehensive Diagnostics

Multi Gene Panel (94 Genes)
Targeted genes: AIP ALK APC ATM BAP1 BLM BMPR1A BRCA1 BRCA2 BRIP1 BUB1B CDC73 CDH1 CDK4 CDKN1C CDKN2A CEBPA CEP57 CHEK2 CYLD DDB2 DICER1 DIS3L2 EGFR EPCAM ERCC2 ERCC3 ERCC4 ERCC5 EXT1 EXT2 EZH2 FANCA FANCB FANCC FANCD2 FANCE FANCF FANCG FANCI FANCL FANCM FH FLCN GATA2 GPC3 HNF1A HRAS KIT MAX MEN1 MET MLH1 MSH2 MSH6 MUTYH NBN NF1 NF2 NSD1 PALB2 PHOX2B PMS1 PMS2 PRF1 PRKAR1A PTCH1 PTEN RAD51C RAD51D RB1 RECQL4 RET RHBDF2 RUNX1 SBDS SDHAF2 SDHB SDHC SDHD SLX4 SMAD4 SMARCB1 STK11 SUFU TMEM127 TP53 TSC1 TSC2 VHL WRN WT1 XPA XPC
Source: Medical Genetics Center

Hereditary Cancer Syndrome: Sequencing Panel

Approximately 5-10% of all cancers are inherited, meaning that pathogenic variants in a single cancer susceptibility gene can predispose an individual to develop cancer and these pathogenic variants can be passed down in families. The risk for developing cancer can vary dramatically from syndrome to syndrome, from about a 55% risk of developing breast cancer in Peutz-Jeghers syndrome to as high as a 100% risk for colon cancer for familial adenomatous polyposis syndrome. Accurate and timely diagnoses are necessary to provide proper medical surveillance and treatment to affected and at-risk individuals.
Targeted genes: (60) AIP, ALK, APC, ATM, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1B, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CHEK2, FH, FLCN, GPC3, MAX, MEN1, MET, MGMT, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF2, PALB2, PHOX2B, PMS2, POLD1, PRKAR1A, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RET, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, WT1, XRCC2
Source: Emory Genetics Laboratory

Invitae Hereditary Cancer Syndromes Panel

The hereditary cancer syndromes panel includes up to 34 genes that can cause adult-onset cancers, including breast cancer, ovarian cancer, uterine cancer, colorectal cancer, and pancreatic cancer as well as other cancer types.
The primary panel includes 33 genes that are associated with breast cancer, ovarian cancer, uterine/endometrial cancer, colorectal cancer, and pancreatic cancer as well as other cancer types. In addition to the primary panel, clinicians can also choose to include a gene, PALLD, that has limited evidence of association.
Source: Invitae


Pin It